Dharwad News Today

Age Related Vision Dysfunction Market Insights and Market Forecast by DelveInsight

 Breaking News
  • No posts were found

Age Related Vision Dysfunction Market Insights and Market Forecast by DelveInsight

July 23
15:35 2021
Age Related Vision Dysfunction Market Insights and Market Forecast by DelveInsight

DelveInsight’s Age-related Vision Dysfunction Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the Age-related Vision Dysfunction, historical and forecasted epidemiology as well as the Age-related Vision Dysfunction market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

Age-Related Vision Dysfunction Overview

The International Classification of Diseases 11 (2018) classifies vision impairment into two groups, distance and near presenting vision impairment. Beginning in the early to mid-forties, most adults may start to experience problems with their ability to see clearly at close distances, especially for reading and computer tasks. This normal change in the eye’s focusing ability will continue to progress over time. Vision loss among the elderly population is a major health care problem. Approximately one in three people have some form of vision-reducing eye disease by the age of 65. Beginning in the early to mid-forties, most adults may start to experience problems with their ability to see clearly at close distances, especially for reading and computer tasks. This normal change in the eye’s focusing ability will continue to progress over time. Adults over 40 may be particularly at risk for the development of eye and vision problems.

 

Approach free sample copy @ https://www.delveinsight.com/sample-request/age-related-vision-dysfunction-market

 

Regions Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

 

Key companies involved in the Age-Related Vision Dysfunction report

1. AGN-190584 (Allergan [acquired by AbbVie])

2. MicroLine/Pilocarpine Ophthalmic (Eyenovia)

3. PresbiDrops/CSF-1 (Orasis Pharmaceuticals)

4. Zimura/ Avacincaptad pegol (IVERIC Bio)

5. ALK-001 (Alkeus Pharmaceuticals)

6. ONS-5010/Lytenava/Bevacizumab-vikg (Outlook Therapeutics)

7. KSI-301 (Kodiak Sciences)

8. Faricimab (Roche)

9. Abicipar (Allergan [acquired by AbbVie]/Molecular Partners)

10. RGX-314 (Regenxbio)

11. Beovu/RTH258/Brolucizumab (Novartis)

12. STN1013001/DE-130A/Catioprost and latanoprost emulsion (Santen SAS)

13. NCX 470 (Nicox Ophthalmics)

14. OTX-TP/Travoprost ophthalmic insert (Ocular Therapeutix)

15. PDP-716 (Sun Pharma Advanced Research Company Limited)

16. OPT-302 (Opthea)

17. Lumitin/Conbercept (Chengdu Kanghong Pharmaceuticals)

18. AKST4290/Lazucirnon (Alkahest)

19. GT005 (Gyroscope Therapeutics)

20. ADVM-022 (Adverum Biotechnologies)

21. Emixustat hydrochloride (Kubota Vision)

22. KVD001 (KalVista Pharmaceuticals)

23. Luminate/ALG-1001/Risuteganib (Allergo Opthalmics and Baush Health)

24. GB-102 (Graybug Vision)

25. Razuprotafib/AKB-9778 (Aerpio Pharmaceuticals)

26. Nyxol/Phentolamine Mesylate (Ocuphire Pharma)

27. STN1012600/DE-126 (Santen Pharmaceutical)

28.  And many others

 

Age-related Vision Dysfunction Drugs

  • Rhopressa/Rhokiinsa/ Netarsudil mesylate (Aerie Pharmaceuticals)
  • Rocklatan/Latanoprast and Netarsudil Dimesylate (Aerie Pharmaceuticals)
  • Xelpros/Latanoprost (Sun Pharma Advanced Research Company Limited)
  • Lucentis/Ranibizumab (Genentech and Novartis)
  • Eylea/Aflibercept (Bayer, Regeneron Pharmaceuticals, and Santen)
  • Vyzulta/Latanoprostene Bunod Ophthalmic Solution (Bausch & Lomb and Nicox)
  • And many others

 

Age-related Vision Emerging Drugs

  • AGN-190584 (Allergan [acquired by AbbVie])
  • Faricimab (Hoffman La Roche)
  • PresbiDrops/CSF-1 (Orasis Pharmaceuticals)
  • RGX-314 (Regenxbio)
  • MicroLine/Pilocarpine Ophthalmic (Eyenovia)
  • KSI-301 (Kodiak Sciences)
  • And many others

 

Age-related Vision Dysfunction Symptoms

Some of the common symptoms include difficulty reading and doing close work, problems with glare, changes in color perception, reduced tear production, seeing distorted images, loss of side vision, seeing floaters and flashes, and fluctuating vision.

 

Age-related Vision Dysfunction Diagnosis

The comprehensive adult eye and vision examination provide the means to evaluate the function and health of the eyes and visual system and to obtain information to diagnose the cause of signs noted by the examiner or symptoms reported by the patient. It also provides the means to identify the presence of other ocular or systemic conditions that may exist without symptoms.

 

Age-related Vision Dysfunction Treatment

Current clinical management of presbyopia in the United States includes off-label treatment using miotic agents, such as pilocarpine and carbachol. Pharmacological treatment of presbyopia is based on using ophthalmic drops, which by the impact on the ciliary muscle, changes the pupil size and elasticity, improving near vision. Many different modifications, including the combination of two parasympathomimetics and an NSAID, two parasympathomimetics and one parasympatholytic, carbachol 2.25% with brimonidine 0.2%, and a combination of pilocarpine 0.247%, phenylephrine 0.78%, polyethylene glycol 0.09%, nepafenac 0.023%, pheniramine 0.034%, and naphazoline 0.003% were studied.

 

Age-related Vision Dysfunction Market Insights

The effect on an elderly persons’ lifestyle can be quite thoughtful and lead to dependency. There are effective interventions covering prevention, treatment, and rehabilitation that address the needs related to eye conditions and vision impairment; some are among the most cost-effective and feasible of all health care interventions to implement. Moreover, vision rehabilitation is very effective in improving functioning for people with an irreversible vision impairment that can be caused by eye conditions such as diabetic retinopathy, glaucoma, consequences of trauma, and age-related macular degeneration, etc.

 

Age-related Vision Dysfunction Market Forecast

If further reduction of IOP is necessary, other drugs such as epinephrine, miotics, carbonic anhydrase inhibitors, alpha2 agonists, and prostaglandin analogs are added in a stepwise pattern. In Japan, the most frequently prescribed antiglaucoma medications are prostaglandin analogs (PGs); however, in recent years, fixed combination therapy has emerged as a major treatment.

 

Age-related Vision Dysfunction Market Report Scope

  • The report covers the descriptive overview of Age-related Vision Dysfunction, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.
  • Comprehensive insight has been provided into the Age-related Vision Dysfunction epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Age-related Vision Dysfunction is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Age-related Vision Dysfunction market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
  •  The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Age-related Vision Dysfunction market.

 

Approach free sample copy @ https://www.delveinsight.com/sample-request/age-related-vision-dysfunction-market

 

Read Detailed Table of Content

1. Key Insights

2. Report Introduction

3. Age-related Vision Dysfunction Market Overview at a Glance

4. Executive Summary of Age-related Vision Dysfunction

5. Epidemiology and Market Methodology

6. Disease Background and Overview

7. Diagnosis of Age-related Vision Dysfunction

8. Prevention of Age-related Vision Dysfunction

9. Diagnostic Guidelines

10. Current Treatment Practices: Age-related Vision Dysfunction

11. Treatment Guidelines

12. Epidemiology and Patient Population

13. The United States

14. EU-5

15. Japan

16. Patient Journey

17. Key Endpoints in Age-related Vision Dysfunction Clinical Trials

18. Marketed Therapies

19. Emerging Therapies

20. Age-related Vision Dysfunction: 7 Major Market Analysis

21. The United States Market Size

22. EU-5 Market Size

23. Japan

24. Market Access and Reimbursement

25. Market Drivers

26. Market Barriers

27. SWOT Analysis

28. Unmet Needs

29. Appendix

30. DelveInsight Capabilities

31. Disclaimer

32. About DelveInsight

 

Age-related Vision Dysfunction Market Report Highlights

  • In the coming years, the Age-related Vision Dysfunction market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Age-related Vision Dysfunction R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Age-related Vision Dysfunction. The launch of emerging therapies will significantly impact the Age-related Vision Dysfunction market.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Age-related Vision Dysfunction.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

 

Why should you buy this report?

  • The report will help in developing business strategies by understanding trends shaping and driving the Age-related Vision Dysfunction market.
  • To understand the future market competition in the Age-related Vision Dysfunction market and an Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Age-related Vision Dysfunction in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Age-related Vision Dysfunction market.
  • To understand the future market competition in the Age-related Vision Dysfunction market.

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

 

Contact Us

Shruti Thakur

[email protected]

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/dimapurnewsdesk/dharwadnewstoday.org/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share